AstraZeneca's Tagrisso plus Orpathys cuts progression risk 45% in MET-driven lung cancer

AstraZeneca's Tagrisso plus Orpathys reduced the risk of disease progression or death by 45% and the risk of death by 32% in MET-driven EGFR-mutated lung cancer after progression on Tagrisso.

Detected & updated continuously · Source: Nebula